ENGN (enGene Holdings) Debt-to-Revenue : N/A (As of Jul. 2024)

View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

enGene Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $1.76 Mil. enGene Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $23.09 Mil. enGene Holdings's annualized Revenue for the quarter that ended in Jul. 2024 was $0.00 Mil.

enGene Holdings Debt-to-Revenue Historical Data

The historical data trend for enGene Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enGene Holdings Debt-to-Revenue Chart

enGene Holdings Annual Data

Trend

Oct20

Oct21

Oct22

Oct23

Debt-to-Revenue

N/A

enGene Holdings Quarterly Data
	Oct20	Oct21	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Debt-to-Revenue	Get a 7-Day Free Trial							N/A	N/A	N/A	N/A	N/A

Competitive Comparison of enGene Holdings's Debt-to-Revenue

For the Biotechnology subindustry, enGene Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

enGene Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where enGene Holdings's Debt-to-Revenue falls into.

enGene Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

enGene Holdings's Debt-to-Revenue for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.562	+	9.216)	/	N/A
	=	N/A

enGene Holdings's annualized Debt-to-Revenue for the quarter that ended in Jul. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.763	+	23.092)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jul. 2024) Revenue data.

enGene Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of enGene Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

enGene Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9

Website

https://www.engene.com

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Executives

Forbion Growth Opportunities Fund I Cooperatief U.a.	10 percent owner	GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Richard M Glickman	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson	director, officer: Chief Executive Officer	8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Gerald A Brunk	director	C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos	director	BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan	officer: Int. Chief Financial Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung	officer: Chief Technology Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols	officer: Pres. & Chief Operating Ofc.	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan	officer: Chief Scientific Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v.	10 percent owner	GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Management B.v.	10 percent owner	C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807